PMID- 36452059
OWN - NLM
STAT- MEDLINE
DCOM- 20221202
LR  - 20221202
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2022
DP  - 2022
TI  - Investigating the Mechanism of Rhizoma Coptidis-Eupatorium fortunei Medicine in 
      the Treatment of Type 2 Diabetes Based on Network Pharmacology and Molecular 
      Docking.
PG  - 7978258
LID - 10.1155/2022/7978258 [doi]
LID - 7978258
AB  - OBJECTIVE: This study systematically explored the mechanism of Rhizoma 
      Coptidis-Eupatorium fortunei in treating type 2 diabetes mellitus (T2DM) by using 
      network pharmacology and molecular docking methods. METHODS: The TCMSP database 
      was used to screen out the active ingredients and related targets of Rhizoma 
      Coptidis-Eupatorium fortunei (R-E) drug pair. GeneCards, OMIM, DrugBank, and 
      other databases were used to screen the related targets of T2DM, and then, the 
      UniProt database was used to standardize the relevant targets of T2DM. Then, the 
      Venn analysis was performed on the active ingredient-related targets and 
      disease-related targets of R-E drugs to find the intersection targets. Using the 
      STRING database and Cytoscape software, the PPI network and "drug-active 
      ingredient-target-disease" network are constructed by intersecting targets and 
      corresponding active ingredients. Through the cluster profiler package in the R 
      software, GO function enrichment analysis and KEGG pathway enrichment analysis 
      were carried out on the intersection targets and the screened core targets, and 
      the prediction results were verified by molecular docking. RESULTS: Taking OB >/= 
      30% and DL >/= 0.18 as the standard, a total of 25 effective active ingredients of 
      R-E drug pairs were screened, including berberine, palmatine, coptisine, and so 
      on. After corresponding, 19 effective chemical components and 284 targets of the 
      R-E drug pair were obtained. After searching multiple disease databases, 1289 
      T2DM-related targets were screened. After the summary, 159 common targets were 
      obtained in this study. Finally, in the bioinformatics analysis, this study 
      concluded that quercetin, luteolin, berberine, palmatine, and coptisine are the 
      main chemical components of the R-E drug pair. ESR1, MAPK1, AKT1, TP53, IL6, and 
      JUN are the important core targets. GO and KEGG enrichment analyses showed that 
      Rhizoma Coptidis-Eupatorium fortunei could improve T2DM by regulating multiple 
      biological processes and pathways. Molecular docking results showed that 
      berberine, palmatine, and coptisine had higher binding to the core target, and 
      MAPK1, AKT1, and IL6 could stably bind to the active ingredients of Rhizoma 
      Coptidis-Eupatorium fortunei. CONCLUSION: Rhizoma Coptidis-Eupatorium fortunei 
      may have therapeutic effects on T2DM such as anti-inflammatory and regulating 
      glucose and lipid metabolism through multiple components, multiple targets, and 
      multiple signaling pathways, which provides a scientific basis for further 
      research on the hypoglycemic effect of Rhizoma Coptidis-Eupatorium fortunei drug 
      pair.
CI  - Copyright (c) 2022 Huan Li et al.
FAU - Li, Huan
AU  - Li H
AUID- ORCID: 0000-0002-8991-9624
AD  - First Clinical Medical College, Shandong University of Traditional Chinese 
      Medicine, Jinan 250014, China.
FAU - Luo, Dan
AU  - Luo D
AD  - Department of Endocrinology, Affiliated Hospital of Shandong University of 
      Traditional Chinese Medicine, Jinan 250014, China.
FAU - Wei, Ran
AU  - Wei R
AD  - First Clinical Medical College, Shandong University of Traditional Chinese 
      Medicine, Jinan 250014, China.
AD  - Department of Science and Technology, Affiliated Hospital of Shandong University 
      of Traditional Chinese Medicine, Jinan 250014, China.
FAU - Sun, Mingliang
AU  - Sun M
AD  - Department of Endocrinology, Affiliated Hospital of Shandong University of 
      Traditional Chinese Medicine, Jinan 250014, China.
FAU - Zhang, Xi
AU  - Zhang X
AD  - College of Traditional Chinese Medicine, Shandong University of Traditional 
      Chinese Medicine, Jinan 250014, China.
FAU - Deng, Huan
AU  - Deng H
AD  - First Clinical Medical College, Shandong University of Traditional Chinese 
      Medicine, Jinan 250014, China.
FAU - Bian, Wenfei
AU  - Bian W
AD  - College of Traditional Chinese Medicine, Shandong University of Traditional 
      Chinese Medicine, Jinan 250014, China.
FAU - Wei, Haoyue
AU  - Wei H
AD  - College of Traditional Chinese Medicine, Shandong University of Traditional 
      Chinese Medicine, Jinan 250014, China.
FAU - Huang, Yanqin
AU  - Huang Y
AUID- ORCID: 0000-0001-7249-9427
AD  - Department of Endocrinology, Affiliated Hospital of Shandong University of 
      Traditional Chinese Medicine, Jinan 250014, China.
LA  - eng
PT  - Journal Article
DEP - 20221121
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0I8Y3P32UF (Berberine)
RN  - 0 (Interleukin-6)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Molecular Docking Simulation
MH  - *Eupatorium
MH  - *Drugs, Chinese Herbal/pharmacology
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Berberine
MH  - Network Pharmacology
MH  - Interleukin-6
MH  - *Antineoplastic Agents
PMC - PMC9705109
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/02 06:00
MHDA- 2022/12/03 06:00
PMCR- 2022/11/21
CRDT- 2022/12/01 02:35
PHST- 2022/07/13 00:00 [received]
PHST- 2022/10/08 00:00 [revised]
PHST- 2022/10/21 00:00 [accepted]
PHST- 2022/12/01 02:35 [entrez]
PHST- 2022/12/02 06:00 [pubmed]
PHST- 2022/12/03 06:00 [medline]
PHST- 2022/11/21 00:00 [pmc-release]
AID - 10.1155/2022/7978258 [doi]
PST - epublish
SO  - Biomed Res Int. 2022 Nov 21;2022:7978258. doi: 10.1155/2022/7978258. eCollection 
      2022.